EUCTR2010-024266-21-IT进行中（未招募）不适用
A phase II study of metronomic oral chemotherapy with cyclophosphamide plus capecitabine and vinorelbine in metastatic breast cancer patients
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •- Pre- or post-menopausal women (age =18 years) with histologically or citologically (cell block) proven, locally advanced (inoperable) or metastatic breast carcinoma. Immunohistochemical evaluation of ER, PgR, HER2, and EGFR according to EIO (European Institute of oncology) guidelines is mandatory.
- •- Patients with ER>1% and/or PgR >1%
- •- Patients with HER-2/neu overexpressed tumors, are eligible if they had received previous trastuzumab therapy for advanced disease, and/or a treatment with anti HER2 targeted therapy.
- •- Patients fulfilling one of the following criteria:
- •- Patients with measurable disease as per RECIST 1.1 criteria. This is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as = 20 mm with conventional techniques or as = 10 mm with spiral CT scan
- •- Patients with bone lesions, lytic or mixed (lytic + sclerotic), in the absence of measurable disease as defined by RECIST 1.1 criteria. Bone lesions must be evaluable by plain CT or MRI. Patients with lesions identified only on radionucleotide bone scan are not eligible.
- •- Patients may have received any primary and/or adjuvant therapies, as any previous lines of chemotherapy and endocrine therapy for advanced disease. Patients may have received metronomic capecitabine, methotrexate and cyclophosphamide in adjuvant setting at least 12 months before study entry
- •- Previous treatment with capecitabine, cyclophosphamide and vinorelbine not in metronomic schedule for advanced disease is allowed, provided that the patient has progressive disease at study entry and the patients should not be defined as refractory” to treatments (PR or CR or SD > 6 months).
- •- Patients may have had previous hormonal therapy as treatment of metastatic disease provided that the patient has progressive disease at study entry. Hormonal therapy must be discontinued prior to study entry, excluding LH-RH analogue
- •- Life expectancy greater than 6 months.
- •- ECOG performance status =2
- •- Patients must have normal organ and marrow function
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •Previous metronomic chemotherapy for advanced disease with capecitabine, cyclophosphamide and vinorelbine
- •- Triple negative subtypes (ER: 0% PgR:0% Her2: negative)
- •- Patients defined as refractory” to capecitabine, cyclophosphamide and vinorelbine (PD or SD < 6 months).
- •- Presence of sintomatic cerebral or leptomeningeal involvement.
- •- Previous or concomitant other malignancy except basal or squamous cell carcinoma of the skin or adequately treated in situ carcinoma of the cervix.
- •- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •- Malabsorption syndrome or disease affecting significantly gastrointestinal function or major resection of the stomach or proximal small bowel that could affect absorption of oral vinorelbine
- •- Concurrent treatment with any other anti-cancer therapy except LHRH analogue.
- •- Patients with pre-existing motor or sensory peripheral neuropathy grade 2 according to NCI criteria
研究者
相似试验
进行中（未招募）
不适用
A phase II study of metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with bevacizumab and erlotinib (BEXE), plus trastuzumab in HER2/neu positive tumors (BEXET), in advanced breast canceradvanced or metastatic breast cancerMedDRA version: 14.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-006025-27-ITISTITUTO EUROPEO DI ONCOLOGIA
进行中（未招募）
不适用
A phase II study of metronomic oral chemoterapy with Cyclophosphamide plus Capecitabine combined with Trastuzumab in advanced breast cancer - NDPre-or post-menopausal women with histologically proven, locally advanced (inoperable) or metastatic breast cancer.EUCTR2009-017083-16-ITGOIM GRUPPO ONCOLOGICO MERIDIONALE
进行中（未招募）
1 期
Metronomic chemotherapy in elderly non-fit patients with aggressive B-Cell lymphomas. Phase II studyB-Cell lymphomasMedDRA version: 21.0Level: LLTClassification code 10012855Term: Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation)System Organ Class: 100000004864EUCTR2016-003703-62-ITFONDAZIONE ITALIANA LINFOMI ONLUS60
进行中（未招募）
1 期
Phase 2 trial evaluating metronomic chemotherapy in patients with relapsed or refractory Wilms tumorEUCTR2021-002540-67-FRCentre Oscar Lambret28
已完成
3 期
ANZ 0001 Capecitabine vs CMF in Advanced Breast CancerAdvanced breast cancerACTRN12606000379516Breast Cancer Trials (formerly Australian New Zealand Breast Cancer Trials Group)325